The impact of the COVID-19 pandemic on the small cell lung cancer epidemiology
Abstract Objectives To explore the potential impact of the coronavirus disease 2019 (COVID-19) pandemic on the epidemiology of small-cell lung cancer (SCLC). Methods SCLC patients were collected from the Surveillance, Epidemiology, and End-Results (SEER) database (diagnosed between 2018 and 2021) an...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-06-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-02816-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850218430461902848 |
|---|---|
| author | Xuemei Zhang Lele Chang Wansu Xu |
| author_facet | Xuemei Zhang Lele Chang Wansu Xu |
| author_sort | Xuemei Zhang |
| collection | DOAJ |
| description | Abstract Objectives To explore the potential impact of the coronavirus disease 2019 (COVID-19) pandemic on the epidemiology of small-cell lung cancer (SCLC). Methods SCLC patients were collected from the Surveillance, Epidemiology, and End-Results (SEER) database (diagnosed between 2018 and 2021) and grouped according to the timing of the COVID-19 pandemic. Intergroup comparisons and survival analyses were performed on clinicopathologic characteristics and survival data to explore the differences in morbidity characteristics and survival in SCLC patients before and after the pandemic. Results SCLC Patients diagnosed in the post-COVID-19 pandemic tended to have earlier tumor stage, receive chemotherapy (OR 1.14, 95% CI 1.02–1.27, P-value = 0.02) rather than radiotherapy (OR 0.89, 95% CI 0.84–0.96, P-value < 0.01), and have increased time to treatment delay. Balancing follow-up time and constructing improved survival curves, patients with SCLC diagnosed after the pandemic tended to have a worse prognosis. Conclusions Differences in some clinicopathologic factors and treatment choices, or the pandemic itself, may result in a tendency for patients with SCLC diagnosed after the pandemic to have a worse prognosis, alerting clinicians to the need to focus on the management and treatment of this population. |
| format | Article |
| id | doaj-art-23d43df86c5e4fb8b5df5f5d38be80ae |
| institution | OA Journals |
| issn | 2730-6011 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Oncology |
| spelling | doaj-art-23d43df86c5e4fb8b5df5f5d38be80ae2025-08-20T02:07:45ZengSpringerDiscover Oncology2730-60112025-06-0116111310.1007/s12672-025-02816-5The impact of the COVID-19 pandemic on the small cell lung cancer epidemiologyXuemei Zhang0Lele Chang1Wansu Xu2Department of Radiation Oncology, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People’s HospitalDepartments of Gynecology, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fujian Medical UniversityDepartment of Radiation Oncology, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People’s HospitalAbstract Objectives To explore the potential impact of the coronavirus disease 2019 (COVID-19) pandemic on the epidemiology of small-cell lung cancer (SCLC). Methods SCLC patients were collected from the Surveillance, Epidemiology, and End-Results (SEER) database (diagnosed between 2018 and 2021) and grouped according to the timing of the COVID-19 pandemic. Intergroup comparisons and survival analyses were performed on clinicopathologic characteristics and survival data to explore the differences in morbidity characteristics and survival in SCLC patients before and after the pandemic. Results SCLC Patients diagnosed in the post-COVID-19 pandemic tended to have earlier tumor stage, receive chemotherapy (OR 1.14, 95% CI 1.02–1.27, P-value = 0.02) rather than radiotherapy (OR 0.89, 95% CI 0.84–0.96, P-value < 0.01), and have increased time to treatment delay. Balancing follow-up time and constructing improved survival curves, patients with SCLC diagnosed after the pandemic tended to have a worse prognosis. Conclusions Differences in some clinicopathologic factors and treatment choices, or the pandemic itself, may result in a tendency for patients with SCLC diagnosed after the pandemic to have a worse prognosis, alerting clinicians to the need to focus on the management and treatment of this population.https://doi.org/10.1007/s12672-025-02816-5Small cell lung cancerCOVID-19DiagnosisRadiotherapyPrognosis |
| spellingShingle | Xuemei Zhang Lele Chang Wansu Xu The impact of the COVID-19 pandemic on the small cell lung cancer epidemiology Discover Oncology Small cell lung cancer COVID-19 Diagnosis Radiotherapy Prognosis |
| title | The impact of the COVID-19 pandemic on the small cell lung cancer epidemiology |
| title_full | The impact of the COVID-19 pandemic on the small cell lung cancer epidemiology |
| title_fullStr | The impact of the COVID-19 pandemic on the small cell lung cancer epidemiology |
| title_full_unstemmed | The impact of the COVID-19 pandemic on the small cell lung cancer epidemiology |
| title_short | The impact of the COVID-19 pandemic on the small cell lung cancer epidemiology |
| title_sort | impact of the covid 19 pandemic on the small cell lung cancer epidemiology |
| topic | Small cell lung cancer COVID-19 Diagnosis Radiotherapy Prognosis |
| url | https://doi.org/10.1007/s12672-025-02816-5 |
| work_keys_str_mv | AT xuemeizhang theimpactofthecovid19pandemiconthesmallcelllungcancerepidemiology AT lelechang theimpactofthecovid19pandemiconthesmallcelllungcancerepidemiology AT wansuxu theimpactofthecovid19pandemiconthesmallcelllungcancerepidemiology AT xuemeizhang impactofthecovid19pandemiconthesmallcelllungcancerepidemiology AT lelechang impactofthecovid19pandemiconthesmallcelllungcancerepidemiology AT wansuxu impactofthecovid19pandemiconthesmallcelllungcancerepidemiology |